@article{article, title  = {{Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{https://eprints.whiterose.ac.uk/171150/ }},

 year = {{2020}},

 month = {{12}},

 author = {{Eisen T and Frangou E and Oza B and Ritchie AWS and Smith B and Kaplan R and Davis ID and Stockler MR and Albiges L and Escudier B and Larkin J et al}},

 doi = {{10.1200/jco.20.01800}},

 volume = {{38}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{34}},

 pages = {{4064-4075}},

 note = {{Accessed on 2024/12/21}}}